Research identifies vascular smooth muscle cell loss as a key factor for cerebrovascular reactivity impairment in Alzheimer’s disease, suggesting new treatment avenues.
These findings identify VSMC degeneration as an important driver of CVR impairment independent of cerebral amyloid angiopathy or inflammation, highlighting vascular integrity as a potential therapeutic target in ADRD.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: